CDNA Stock Analysis: Buy, Sell, or Hold?
CDNA - CareDx, Inc.
$48.61
1.62 (3.45%)
â˛
5d:
+7.26%
30d:
+29.25%
90d:
+125.36%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When CDNA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CDNA is fairly priced but lacks strong directional signals. At 17.1% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CDNA is fairly priced but lacks strong directional signals. At 17.1% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$44.02
Based on 7.9% avg growth
INTRINSIC VALUE TODAY
$27.33
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CDNA is currently trading at $48.61, which is considered slightly high relative to its 30-day fair value range of $35.21 to $47.05. From a valuation perspective, the stock is trading at a premium (Forward PE: 35.9) compared to its historical average (22.3). At these levels, the market is pricing in 17.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CDNA is in a strong uptrend. The price is approaching resistance at $48.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: CDNA scores 27/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CDNA is in a strong uptrend. The price is approaching resistance at $48.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.4% recently.
Market Sentiment: CDNA scores 27/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$35.21 -
$47.05
Company Quality Score
35/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
41.9%
Protect Your Profits
CDNA is technically overbought (RSI 72). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Weak technical setup (27/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.4%)
- NEUTRAL: Near Wall St target ($52.33)
- NEUTRAL: Trading at premium valuation - market expects 17.1% growth which is achievable
- WARNING: Composite score 35/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$35.21 -
$47.05
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$44.80
Resistance Level
$48.72
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
35.87
Wall Street Target
$52.33
(+7.7%)
Revenue Growth (YoY)
52.2%
Profit Margin
24.2%
Valuation Premium vs History
+17.1% premium
PE vs Historical
35.9 vs 22.3
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+17.1%
(market-implied from PE analysis)
1-Year Target
$56.92
(+17%)
2-Year Target
$66.66
(+37%)
3-Year Target
$78.05
(+61%)
3-Yr Target (if PE normalizes)
(PE: 36â22)
PE COMPRESSION
$48.52
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 35.9, Growth: 11.7%)
$67.71
(+39%)
Base:
(SPY PE: 20.1, Growth: 11.7%)
$37.88
(-22%)
Bear:
(PE: 17.1, Growth: 11.7%)
$32.20
(-34%)
đ
Valuation based on Current Earnings
Trailing PE: 22.38 | Current EPS (TTM): $2.10
Bull Case
$33.35
(-31%)
Analyst growth -35.5%, PE expands to 24.6
Base Case
$30.32
(-38%)
Market implied -35.5%, PE stable at 22.4
Bear Case
$31.95
(-34%)
Severe decline -20.0%, PE contracts to 19.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 22, 2026 2:52 PM ET
Data refreshes hourly during market hours. Next update: 3:52 PM
Data refreshes hourly during market hours. Next update: 3:52 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CDNA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
John Walter Hanna Jr
SELL
10282 shares
2026-04-16
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher ScientificâĻ |
STRONG BUY
31 analysts |
$631 | 41 HOLD |
|
EXAS
EXACT Sciences CorporatiâĻ |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$194 | 50 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$228 | 43 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$331 | 38 SELL |
Advanced CDNA Option Strategies
Professional options setups generated by AI based on today's CDNA price and gamma walls.
